Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of A-101 Topical Solution for the Treatment of Common Warts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03691831
Recruitment Status : Completed
First Posted : October 2, 2018
Last Update Posted : October 29, 2019
Sponsor:
Information provided by (Responsible Party):
Aclaris Therapeutics, Inc.

Brief Summary:
Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts

Condition or disease Intervention/treatment Phase
Common Wart Drug: A-101 Other: Vehicle Phase 3

Detailed Description:
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 502 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The blinded vehicle solution is packaged to match the active study drug and will be stored under the same conditions.
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts
Actual Study Start Date : September 13, 2018
Actual Primary Completion Date : April 21, 2019
Actual Study Completion Date : July 9, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Arm Intervention/treatment
Active Comparator: A-101
Topical solution, hydrogen peroxide 45%
Drug: A-101
hydrogen peroxide 45% topical solution
Other Name: hydrogen peroxide 45%

Placebo Comparator: Vehicle
Topical solution, isopropyl alcohol and water
Other: Vehicle
Vehicle solution containing isopropyl alcohol and water
Other Name: isopropyl alcohol and sterile water




Primary Outcome Measures :
  1. The primary efficacy endpoint is the proportion of subjects whose identified common warts are determined to be clear on the PWA scale (PWA=0) [ Time Frame: Day 60 ]

    The primary efficacy endpoint is the proportion of subjects whose identified common warts are determined to be clear on the PWA scale (PWA=0) at Visit 10 (Day 60).

    Efficacy will be assessed using the Physician's Wart Assessment Scale (PWA) which is a 4 point scale



Secondary Outcome Measures :
  1. Proportion of subjects who achieve complete clearance of all identified common warts (PWA =0). [ Time Frame: Day 137 ]
    Complete clearance of all identified common warts will be assessed using the Physician's Wart Assessment Scale (PWA) which is a 4 point scale.

  2. Comparison between A-101 45% and Vehicle of the mean per subject percent of treated warts that are clear (PWA=0) [ Time Frame: Day 137 ]
    Clearance of all treated warts will be assessed using the PWA scale which is a four point scale.

  3. Comparison between A-101 45% and Vehicle of the proportion of subjects with a single wart at baseline, whose wart is clear (PWA=0). [ Time Frame: Day 60 ]
    Clearance of the single wart at baseline will be assessed using the PWA scale which is a four point scale.

  4. Comparison between A-101 45% and vehicle with respect to the median time to achieve onset of clearance (PWA=0) for all treated warts. [ Time Frame: Day 137 ]
    Clearance of all treated warts will be assessed using the PWA scale which is a four point scale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject or legal guardian is able to comprehend and is willing to sign an informed consent/assent for participation in this study.
  2. Male or female ≥ 2 years old.
  3. Subject has a clinical diagnosis of common warts (verruca vulgaris).
  4. Subject has at least 1 and up to 6 clearly identifiable common warts located on the trunk or extremities that meet the requirements as defined below:

    1. Have a longest axis that is ≥3 and ≤8 mm and have a thickness of ≤3mm
    2. Be a discrete lesion, i.e. each wart meeting the entry criteria is clearly separated from other warts.
    3. Be present for at least 4 weeks
    4. Not be covered with hair which, in the investigator's opinion, would interfere with the study medication treatment or the study evaluations
    5. Not be in an intertriginous fold
    6. Periungual, subungual, genital, anal, mosaic, plantar, flat and filiform warts are excluded from treatment and evaluation. If a subject has these types of warts, but also has warts that meet the inclusion criteria, the subject will NOT be excluded from the study.
  5. Each common wart identified for treatment must have a PWA ≥ 2.
  6. Subject's chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value(s) as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization.
  7. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of the identified common warts or which exposes the subject to an unacceptable risk by study participation.
  8. Subject is willing and able to follow all study instructions and to attend all study visits.
  9. Subject must be the only individual in a household participating in the study.

Exclusion Criteria:

  1. Subject has clinically atypical common warts.
  2. Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.).
  3. Subject has a history of Human Immunodeficiency Virus (HIV) infection.
  4. Subject has had any Human Papilloma Virus (HPV) vaccine within 6 months prior to Visit 1.
  5. Subject has used any of the following intralesional therapies within the specified period prior to Visit 2:

    1. Immunotherapy (e.g., Candida antigen, mumps antigen, Trichophyton antigen); 8 weeks
    2. Anti-metabolite therapy (e.g., bleomycin, 5-fluorouracil); 8 weeks
  6. Subject has used any of the following systemic therapies within the specified period prior to Visit 2:

    1. Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept, infliximab); 16 weeks
    2. Glucocorticosteroids (inhaled and intra-nasal steroids are permitted); 28 days
  7. Subject has used any of the following topical therapies within the specified period prior to Visit 2 on, or in the proximity to any of the common warts identified for treatment, that in the investigator's opinion interferes with the study medication treatment or the study assessments:

    1. LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL], photodynamic therapy [PDT]); 180 days
    2. Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester[SADBE], etc.) 12 weeks
    3. Liquid nitrogen, electrodesiccation, curettage; 60 days
    4. Hydrogen peroxide; 90 days
    5. Antimetabolite therapy (e.g., 5-fluorouracil); 8 weeks
    6. Retinoids; 90 days
    7. Over-the-counter (OTC) wart therapies and cantharidin; 28 days
  8. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in the proximity to any of the common warts identified for treatment that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:

    1. Cutaneous malignancy; 180 days
    2. Sunburn; currently
    3. Pre-malignancy (e.g., actinic keratosis); currently
  9. Subject has a history of sensitivity to any of the ingredients in the study medications.
  10. Subject has any current skin or systemic disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.
  11. Participation in another therapeutic investigational drug/device trial in which administration of an investigational treatment occurred with 30 days prior to Visit 1.
  12. Subject has an active malignancy.
  13. Subjects is viewed by the Principal Investigator as not being able to complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03691831


Locations
Layout table for location information
United States, Arizona
Aclaris Investigational Site
Glendale, Arizona, United States, 85308
United States, Arkansas
Aclaris Investigational Site
Fort Smith, Arkansas, United States, 72916
United States, California
Aclaris Investigational Site
Encinitas, California, United States, 92024-7700
Aclaris Investigational Site
San Diego, California, United States, 92121
United States, Colorado
Aclaris Investigational Site
Denver, Colorado, United States, 80210
United States, Florida
Aclaris Investigational Site
Coral Gables, Florida, United States, 33134
Aclaris Investigational Site
Miami, Florida, United States, 33155
United States, Indiana
Aclaris Investigational Site
New Albany, Indiana, United States, 47150
United States, Maryland
Aclaris Investigational Site
Rockville, Maryland, United States, 20850
United States, Massachusetts
Aclaris Investigational Site
Quincy, Massachusetts, United States, 02169
United States, Missouri
Aclaris Investigational Site
Saint Joseph, Missouri, United States, 64506
United States, Nebraska
Aclaris Investigational Site
Omaha, Nebraska, United States, 68144
United States, New York
Aclaris Investigational Site
Rochester, New York, United States, 14623
United States, North Carolina
Aclaris Investigational Site
Raleigh, North Carolina, United States, 27612
United States, Ohio
Aclaris Investigational Site
Beachwood, Ohio, United States, 44122
United States, Pennsylvania
Aclaris Investigational Site
Upper Saint Clair, Pennsylvania, United States, 15241
United States, South Carolina
Aclaris Investigational Site
Anderson, South Carolina, United States, 29621
United States, Tennessee
Aclaris Investigational Site
Knoxville, Tennessee, United States, 37922
Aclaris Investigational Site
Nashville, Tennessee, United States, 37215
United States, Texas
Aclaris Investigational Site
Arlington, Texas, United States, 76011
Aclaris Investigational Site
College Station, Texas, United States, 77845
Aclaris Investigational Site
Houston, Texas, United States, 77004
United States, Virginia
Aclaris Investigational Site
Lynchburg, Virginia, United States, 24501
Aclaris Investigational Site
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Aclaris Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Judy Schynder Aclaris Therapeutics

Layout table for additonal information
Responsible Party: Aclaris Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03691831    
Other Study ID Numbers: A-101-WART-302
First Posted: October 2, 2018    Key Record Dates
Last Update Posted: October 29, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Warts
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Hydrogen Peroxide
Anti-Infective Agents, Local
Anti-Infective Agents